Switch theme
Sign up to access all valuation multiples
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
1996
1
LTM Revenue n/a
LTM EBITDA n/a
$0.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sangui Biotech Intl has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Sangui Biotech Intl achieved revenue of $0.1M and an EBITDA of -$22K.
Sangui Biotech Intl expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sangui Biotech Intl valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | XXX | XXX | XXX |
| Gross Profit | n/a | $0.1M | XXX | XXX | XXX |
| Gross Margin | NaN% | 95% | XXX | XXX | XXX |
| EBITDA | -$0.2M | -$22K | XXX | XXX | XXX |
| EBITDA Margin | -282% | -32% | XXX | XXX | XXX |
| Net Profit | n/a | -$0.2M | XXX | XXX | XXX |
| Net Margin | NaN% | -287% | XXX | XXX | XXX |
| Net Debt | n/a | $0.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sangui Biotech Intl's stock price is $0.
Sangui Biotech Intl has current market cap of $42K, and EV of $0.9M.
See Sangui Biotech Intl trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.9M | $42K | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sangui Biotech Intl has market cap of $42K and EV of $0.9M.
Sangui Biotech Intl's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Sangui Biotech Intl's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sangui Biotech Intl and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $0.9M | XXX | XXX | XXX |
| EV/Revenue | 12.6x | XXX | XXX | XXX |
| EV/EBITDA | -38.7x | XXX | XXX | XXX |
| P/E | -0.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSangui Biotech Intl's NTM/LTM revenue growth is n/a
Sangui Biotech Intl's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Sangui Biotech Intl's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sangui Biotech Intl's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sangui Biotech Intl and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -88% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 288% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 302% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sangui Biotech Intl acquired XXX companies to date.
Last acquisition by Sangui Biotech Intl was XXXXXXXX, XXXXX XXXXX XXXXXX . Sangui Biotech Intl acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sangui Biotech Intl founded? | Sangui Biotech Intl was founded in 1996. |
| Where is Sangui Biotech Intl headquartered? | Sangui Biotech Intl is headquartered in United States of America. |
| How many employees does Sangui Biotech Intl have? | As of today, Sangui Biotech Intl has 1 employees. |
| Is Sangui Biotech Intl publicy listed? | Yes, Sangui Biotech Intl is a public company listed on PINX. |
| What is the stock symbol of Sangui Biotech Intl? | Sangui Biotech Intl trades under SGBI ticker. |
| Who are competitors of Sangui Biotech Intl? | Similar companies to Sangui Biotech Intl include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sangui Biotech Intl? | Sangui Biotech Intl's current market cap is $42K |
| What is the current revenue growth of Sangui Biotech Intl? | Sangui Biotech Intl revenue growth between 2023 and 2024 was 5%. |
| Is Sangui Biotech Intl profitable? | Yes, Sangui Biotech Intl is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
